-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Chenodiol in Cerebrotendinous Xanthomatosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Chenodiol in Cerebrotendinous Xanthomatosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Chenodiol in Cerebrotendinous Xanthomatosis Drug Details: Chenodiol (Xenbilox, Chenix, Chenofalk) is an...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Roneparstat in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Roneparstat in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Roneparstat in Refractory Multiple Myeloma Drug Details: Roneparstat (SST-0001) is under...
-
Product Insights
Enterocolitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Enterocolitis - Drugs In Development, 2023’, provides an overview of the Enterocolitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Enterocolitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Necrotizing Enterocolitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Necrotizing Enterocolitis - Drugs In Development, 2023’, provides an overview of the Necrotizing Enterocolitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Necrotizing Enterocolitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MPT-0E028 in Metastatic Liver Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MPT-0E028 in Metastatic Liver Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MPT-0E028 in Metastatic Liver Cancer Drug Details: MPT-0E028 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Roneparstat in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Roneparstat in Refractory Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Roneparstat in Refractory Multiple Myeloma Drug Details: Roneparstat (SST-0001) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Chenodiol in Cerebrotendinous Xanthomatosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Chenodiol in Cerebrotendinous XanthomatosisDrug Details:Chenodiol (Xenbilox, Chenix, Chenofalk) is an anticholelithogenic agent which belongs to the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pneumococcal (20-valent) vaccine in Meningitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pneumococcal (20-valent) vaccine in Meningitis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pneumococcal (20-valent) vaccine in Meningitis Drug Details: Vaccine is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MP-0317 in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MP-0317 in Endometrial Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.MP-0317 in Endometrial Cancer Drug Details:MP-0317 is under development for the treatment of...
-
Product Insights
Multiple Myeloma (Kahler Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Multiple Myeloma Pipeline Products Market Report Overview Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. It mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain, and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery. The Multiple Myeloma Drugs in Development market research...